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Up to date, a plethora of protein based materials are used as implants to stimulate tissue 
regeneration or fillers to alleviate tissue or organ impairment. This includes glottal insufficiency, 
urinary bladder incontinence and especially in cosmetic industrial to improve facial contour. 
Once in vivo, protein-based materials are decomposed by cell secreted matrix metalloproteinases 
(MMP) and lose their volume within months [1, 2, 3, 4]. By introducing MMP inhibitor (MMPI), 
the extent of material degradation over time may be reduced. In this dissertation, the 
development of cell-based assay capable of identifying MMPI candidates for protein-based 
implant lifetime prolongation is described. To visualize the degradation, DQ-gelatin, (heavily 
fluorescence labeled gelatin that emits fluorescence signal proportional to its degradation) was 
used to represent the implant material. This gelatin was co-cultured with NIH-3T3 in a 96-well 
plate supplemented with growth media under standard tissue culture condition (5% CO2, 95% 
humidity at 37°C). Number of seeded cells, DQ-gelatin concentration and experiment run time 
were varied to optimize signal-to-noise ratio whilst taking into account more than 80% of seeded 
cells must remain viable. With optimized parameters, 0.8 million cells cultured on cell adhesion 
support scaffold in presence of 50 µg/mL DQ-gelatin for 5 days, the efficacy of BB-94 and 
TIMP-1 as synthetic and natural MMPI candidate were investigated. Both BB-94 and TIMP-1 
were tested at different concentrations according to their IC50 and the approximated amount of 
MMPs in tissue fluid, 20-1000 nM and 0.1-2 µg/mL respectively, to determine their most 
efficient dosage. BB-94 and TIMP-1 demonstrated maximum potential at 72.59±4.75 % and 
60.00±27.41 % at the concentration of 1000 nM and 2 µg/mL respectively. Statistical Analysis 
could not detect the significant difference from varying MMP inhibitor concentration, therefore, 




testing. Because our assay generated reliable statistically distinct signals and are capable of 
detecting quantitative inhibitory efficacy of MMP inhibitors, we believe our novel cell-based 
assay is a feasible method for MMP inhibitor screening that could better represent the complex 
degradation process of protein-based implants in biological systems than the current 
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CHAPTER 1: INTRODUCTION 
 
At present, there are numerous protein-based materials applications [1, 5-11], both in research 
developmental stage and in clinical use. Many are utilized for regenerative purposes such as for 
tissue growth stimulation in cardiac muscle, nerve and cartilage, while some are used as fillers to 
alleviate glottal insufficiency, urinary incontinence and even in while cosmetic industry to 
reduce wrinkles. These materials doubtlessly create a lot of impact in our society; however, in 
most cases, their lifetimes are only a few months after they are implanted. Therefore, it would be 
very beneficial to be able to prolong their retention time in vivo. In this way, the healing efficacy 
of the implant is improved, the duration that the implant provides satisfactory effects would be 
extended and patients would not have to go through the surgical process as often, consequently, 
improving the community living standard. 
 
Once inside the body, protein based materials are degraded the same way as extracellular matrix 
(ECM) turnover [12], which is by enzymatic digestion. These specific groups of enzymes are 
generally referred to as matrix metalloproteinases (MMPs) [13]. They are secreted by both 
residential cells and infiltrated cells recruited during inflammation after wounds through 
laceration, injection or damage of tissue has taken place. By inhibiting MMP activities, the 
retention time of protein-based implants in vivo could be extended. For this reason, our research 
group is interested in identifying suitable MMP inhibitors (MMPis) and has developed a novel 






MMPs are zinc dependent enzymes; all enzymes of this family share a specific structural motif, 
which is zinc binding domain [14, 15]. By introducing agents capable of forming a complex with 
MMPs at this structure, the proteolytic activity of MMPs may be inhibited. These agents are 
referred to as MMP inhibitors. There exist many types of MMPi in nature, the major endogenous 
inhibitors in tissue are the tissue inhibitors of metalloproteinases (TIMPs) [16]. Due to MMP up-
regulation during tumor invasion, a large variety of MMP inhibitors has been synthesized as 
anticancer drugs. They are effective and relatively inexpensive when compare to natural MMP 
inhibitors [14]. 
 
The current technique most associated with the studies of MMP and their inhibitors is 
zymography [17]. Zymography or substrate zymography is an electrophoretic method that has 
been extensively used to study ECM degrading enzymes. It visualizes proteolytic activity based 
on substrate digestion [18]. Zymography does not give accurate quantification of enzymatic 
activity [19] nor does it resembles enzymatic degradation in nature. In this research, we construct 
a cell-based assay prototype capable of screening MMP inhibitors. It provides quantitative data 
on degradation inhibition efficacy together with the effect of the inhibitor on cell viability. By 
focusing on cellular modulated degradation, the information obtained should resemble more of 
the material breakdown after implantation. For substances intended to be used in vivo, they are 
generally introduced into cell culture to evaluate the substance effect on cell apoptosis after their 






In this thesis, we divide our report into 4 chapters, beginning with chapter 1: introduction to give 
an overview of our research. Chapter 2: Literature review provides background information on 
our assay development and the logic behind assay assembly. After the fundamental knowledge 
has been laid down we describe the method and the outcome of our assay development in 
Chapter3: Prototype development. In Chapter 4: Cell-based MMP inhibitor screening assay, the 
result from prototype development were used to assemble our assay and used to examine MMP 
inhibitor efficacy in impeding protein breakdown.  
 
For simplicity, readers whom are only interested in the developed assay may over look chapter 3 
and begin at Cell-based MMP inhibitor screening assay, Chapter 4, as the methodology, result 
and discussion is complete within its own chapter. Readers may only need to refer to chapter 3 
for some repeated methods that has already been described in assay development process. Lastly, 
the future direction of this research is briefly discussed, Chapter 4. 
 
The findings from our research would provide an alternative method for MMP inhibitor efficacy 
evaluation and screening to the conventional zymography technique. By proving the possibility 
of slowing down the degradation of protein-based material using MMP inhibitor, it is highly 
probable that protein-based implant lifetime prolongation may take place and contribute positive 






CHAPTER 2: LITERATURE REVIEW 
1. Introduction 
In this research we develop a cell based assay prototype for screening potential drugs that may 
slow degradation of the protein based materials. For better understanding of our assay, the 
literature review presents the background knowledge necessary for understanding our prototype 
development.  The sections within this chapter include: 
1. Introduction 
2. Implantable biomaterials 
3. Mechanism of degradation 
4. Conventional method and the comparison to our developed prototype  
5. Experiment design and rationale 
5.1. Overview 
5.2. DQ-gelatin 
5.3. Cell type 
5.4. Selected MMP inhibitor: TIMP-1 and BB-94 
5.5. Cell adhesion support scaffold 
5.6. Cell viability testing 
6. Experiment setting 
7. Conclusion 
We first we describe protein-based materials and their retention time in vivo, section 1. Because 
of the benefit in their lifetime prolongation, our research group looks into the mechanism of 
biomaterial degradation, section 2, to design our assay based on the events that take place in vivo 




proteolytic activity, section 3, then compare with our developed prototype. In Experiment design 
and rationale, section 4, we describe a rough picture of our prototype, its each component and 
the logic behind the design. Finally, we summarize our research; how each component is 


















2. Implantable Biomaterials 
When minor laceration occurs, a wound healing mechanism is activated and a proper repair of 
the laceration take place. But once considerable injury where natural regeneration is not 
sufficient happens, biomedical associated technology is required to aid the restoration process.  
Because human regenerative capacity is limited, wrinkles form, organs start to malfunction as 
people age, scarring and loss of tissue function takes place after severe trauma. To heal these 
impairments myriads of biomimetic materials are specifically tailored to provide proper 3-
dimentional micro-environment and stimulants for cell migration, proliferation, differentiation 
and cell organization to form new tissue at the wounded site [20-22]. The materials are also 
engineered to be biocompatible, facilitates transport of nutrients and metabolic waste while 
having similar mechanical properties to its surroundings, and be able to be remodeled and 
replaced at a simultaneous rate with neo-tissue formation. These materials have been intensively 
researched since before 2003 [23]. 
 
While biomimetic implants are utilized in many types of tissue repair including bone [5], 
cartilage [6], nerve [7] and cardiac muscle [8], some are used as space filling agents in the cases 
of glottal insufficiency [9, 10], urinary bladder incontinence [11] and for rhytide alleviation in 
cosmetic field [1]. These materials are called fillers after their function. Others are utilized in 
wound healing stimulations. Because materials with low immunogenicity that hold similar 
mechanical property to its surrounding tissue are generally natural, they are degraded overtime 





Fillers and injectables such as autologous fat have been known since 1893 [24]. It initially was a 
very appealing as it posts no immunological threats, is easy to harvest with numerous accessible 
donor sites and remains for over one year [25]. But due to the large volume loss, its popularity 
has steeply declined. Hyaluronic acid (HA) is one valuable implantable material. They are 
secreted interstitial molecules by variety of cells lineage to maintain tissue viscosity and shock 
absorbance [26] and are crucial in joints and voice production, rendering them preferable for 
vocal fold augmentation [27-31]. Despite their benefits of viscoelastic property, zero 
immunogenicity [32], wound healing stimulation [33] and well established safety and efficacy 
profile [34], HA’s major drawback is its short-lived nature. Although crosslinking has been 
performed in attempt to lengthen its lifetime, HA could only be maintained for only 12 weeks 
[35]. In its natural state, hyaluronic acids have been reported to last less than 2 days 
subcutaneous [36] and 3-5 days inside vocal fold [37].  
 
Extracellular matrixes (ECM) are cell-secreted mixture of interwoven fibrous proteins and 
glycosaminoglycans [38-40], containing small amount of cytokines and growth factors that 
modulates cell behavior [41]. They play a major role in wound healing [42] by stimulating 
angiogenesis, host cells recruitment, adhesion, proliferation, and remodeling of damaged tissue 
[43]. ECM based material can recapitulate natural conditions in vivo [44]. Numerous 
publications have confirmed ECM potential in tissue reconstruction [41] including skin, tissue, 
vessel, tendon and lower urinary tract. Consequently, ECM represent nature’s scaffold for tissue 
repair although their ability to establish complete restoration may be in question since ECM are 





Collagen is the most abundant protein in the ECM as well as in human body [45, 46]. It is a 
natural constituent of connective tissue and the primary structural protein of all our organs [47]. 
Other than providing mechanical support and acting as a reservoir of hormones and growth 
factor, it plays pivotal role in wound healing process [48]. As implantable material, collagen is 
the single substance filler most intensively used and has been manufactured in USA since 1977. 
It has received FDA approval and has become the gold standard used to compare engineered 
materials for soft tissue augmentation of later generations [49]. Over the years, various collagen 
based injectables have been developed and commercialized with different compositions and 
wide-range of residential time in vivo [1, 50-52]. None the less, like other natural materials, all 
forms of collagen correction are temporary and require periodic maintenance [1, 4]. 
 
In short, because of the advantages of implantable protein based materials, both in regeneration 
stimulation and as volume fillers for treatment, they are utilized in a wide range of applications 
and cause large impact on biomedical industry. Regrettably, the main drawbacks of protein based 
implants are their short lived nature; thus lifetime prolongation of these materials would be a 











3. Mechanism of Degradation 
By being able to prolong protein based implant lifetime, their therapeutic efficacy would 
increase, providing many benefits in both the society and the scientific community. For tissue 
regenerative implants such as ECM-based materials, their stimulatory effect of would be 
extended, granting better tissue restoration outcome. For filler type materials, its volume may be 
retained for longer period, thus, widening gaps between each treatment for people who suffer 
glottal insufficiency, urinary bladder incontinence or requiring cosmetic surgery. Therefore, 
patients would be provided with more comforts and may lessen their treatment cost in the long 
run. 
 
To prolong the lifetime of the implant, it is imperative to acknowledge the mechanism of 
material break down. In general, there are 2 different ways that materials are degraded in vivo; 
by hydrolysis and enzymatic digestion [53]. The decomposition of polymer-based implant is 
largely governed by hydrolysis [54], which could easily be controlled by adjusting their chemical 
composition [55]. Our main focus lies on the degradation of protein based materials, where the 
decomposition rate cannot be straightforwardly predicted. 
 
Unlike those of polymer-based, the residence time in vivo of protein-based implant is 
predominated by their host response they elicit. As protein decomposition is tightly regulated by 
cell secreted proteases and is concentrated at cell periphery [56], the higher the material 




the secreted protease per area. If the implant is susceptible to cellular infiltration and is prone to 
enzymatic attack [12] its retention time in vivo is difficult to be prolonged.  
From tissue regeneration point of view, the implant site is similar to an injury with 
subcutaneously embedded foreign body under the skin lesion. The act of incision is enough to 
trigger wound healing, a specific biological process comprise of 5 overlapping independent 
stages to reestablish the integrity of the damage tissue [57, 58]. The progression through 
hemostasis, inflammation, proliferation and remodeling stages make up the wound healing 
sequence [59-61].  
 
Normal healing response take place as soon as tissue is injured [62]. For instance, during a 
surgery where bleeding takes place, hemostasis is activated and blood clot forms, sending out 
chemotactic cues to recruit inflammatory cells such as monocytes and neutrophils to the implant 
cite for pathogen elimination purposes [63]. The immunogenicity determines the extent of 
inflammation. Because the degradation is brought about by both resident and infiltrated cells 
[12], the material porosity influences its degradation rate. Other than surrogating for pathogens, 
neutrophils and macrophages also functions similar to platelets in fibrin clot signaling for 
fibroblast and endothelial cells [64]. They gather at the periwound area, infiltrate the clot, 
proliferate, undergo angiogenesis, lay down extracellular matrix and form new tissue [65]. The 
newly synthesized tissue or the scar tissue is not as strong as the original. The strength of scar 
tissue is approximately only 25% of a normal tissue. After several months its mechanical 
property can be improved by collagen fibers reorganization and cross linking by the fibroblast 




The removal of exogenous implants is similar to the regular process of extracellular matrix 
(ECM) remodeling [12]. Various types of enzymes are secreted by cells within the immediate 
proximity and digest their specific substrates [67]. The well-known ones are the matrix 
metalloproteinases (MMPs) for their involvement with wound healing and normal tissue 
regulation [13]. They are grouped according to their substrates and are critical to the repair 
processes for eliminating necrotic tissue, fibrin clot that forms after bleeding and are also 
necessary in cell migration during inflammatory phase [68]. Table 1 summarizes MMPs, their 
specific substrates and cellular sources [12, 68].   
 
Protein-based implants can be degraded by a diversity of proteases. To mimic the main 
composition of mammalian tissue [69, 70], many of those implants contain collagen. Fibrillar 
collagens function to provide mechanical strength and protect the cells they surround, therefore, 
it is not easily degraded and is resistant to most enzymatic attacks. Collagenase (MMP-1, 8 and 
13) are the specific MMPs with the ability to cleave collagen in their triple helical domain. After 
the cleavage, collagen denature into gelatin at physiological temperature and is susceptible to 
further digestion by numerous enzymes (MMP-1-3, 7-12, 14, 16-19) including gelatinases 
(MMP-2 and 9) [71], making it the easier step in matrix (granulation tissue) remodeling [72]. 
After it is reduced to amino acid, it can be resorbed and re-utilized in cellular protein synthesis.  
 
Because degradation of implant is modulated by cell secreted MMPs, we believe that by 
inhibiting the activity of MMPs, the implant lifetime could be prolonged. Our objective is to 




proteolytic activity. These substances are referred to as the MMP inhibitors (MMPis). Our 
developed assay is a cell-based assay to resemble the phenomena of protein-based implant 
degradation in vivo and to investigate the effect of MMPi on cell viability.  
Table 1 Matrix metalloproteinase and their substrate 
Enzymes Substrates 
Collagenases  
Collagenase-1 (MMP-1) Collagen I, II, III, VII, VIII, X, gelatin, aggrecan, versican, 
proteoglycan link protein, L-selectin, entactin, tenascin, serpins, 
α2- macroglobulin, TNF precursor, MBP, IGFBP-3 
Collagenase-2 (MMP-8) Collagen I, II, III, VII, VIII, X, gelatin, aggrecan, fibronectin, 
laminin, serpins, α2-macroglobulin 
Collagenase-3 (MMP-13) Collagen I, II, III (II>I or III), IV, IX, X, XIV, gelatin, aggrecan, 
perlecan, fibronectin, laminin, tenascin, fibrillin, SPARC, serpins, 
PAI 
Gelatinases  
Gelatinase A, 72 kDa (MMP-
2) 
Gelatin, collagen I, IV, V, VII, X, XI, XIV, aggrecan, versican, 
proteoglycan link protein, fibronectin, laminin, laminin-5, 
tenascin, fibrillin, SPARC, elastin, vitronectin, α2-macroglobulin, 
TNF precursor, MBP, IGFBP-3 
Gelatinase B, 92 kDa (MMP-
9) 
Gelatin, collagen IV, V, VII, X, XIV, aggrecan, versican, nidogen, 
proteoglycan link protein, fibronectin, fibrillin, SPARC,  
entactin,elastin, vitronectin, α1-antitrypsin, α2-macroglobulin, 
TNF precursor,MBP, angiostatin 
Stromelysins  
Stromelysin-1 (MMP-3) Collagen III, IV, V, IX, X, gelatin, versican, nidogen, aggrecan, 
perlecan,proteoglycan link protein, fibronectin, laminin, tenascin, 
fibrillin, SPARC, entactin, elastin, TNF precursor, MBP, IGFBP-3 
Stromelysin-2 (MMP-10) Collagen III, IV, V, gelatin, nidogen, aggrecan, proteoglycan link 
protein, fibronectin, elastin 
Stromelysin-3 (MMP-11) α1-proteinase inhibitor; weak activity on aggrecan, fibronectin, 
laminin 
Matrilysin (MMP-7) Collagen IV, gelatin, versican, nidogen, aggrecan, fibronectin, 
laminin, tenascin, SPARC, elastin, vitronectin, MBP,angiostatin 
Metalloelastase (MMP-12) Collagen IV, gelatin, nidogen, aggrecan, fibronectin, laminin, 
fibrillin, elastin, vitronectin, α1-antitrypsin, TNF precursor, 
angiostatin 
Membrane-type MMPs  
MT1-MMP (MMP-14) Collagen I, II, III, gelatin, nidogen, aggrecan, perlecan, 
fibronectin, laminin, tenascin, vitronectin, fibrillin 
MT2-MMP (MMP-15) Aggrecan, perlecan, fibronectin, laminin, nidogen, tenascin 
MT3-MMP (MMP-16) gelatin, casein 
MT4-MMP (MMP-17) gelatin, TNF precursor 




Other MMPs  
MMP-18, MMP-19 Gelatin 
Enamelysin (MMP-20) Amelogenin 
MMP- 21, 22, 23 Not determined 
***Modified from Vaalamo et al. 
 
By providing information regarding their potency in decreased protein decomposition rate and 
whether they may influence cell apoptosis, we believe implant lifetime prolongation is a very 
possible advancement in medical and biomaterial field that may eventually propel the society 




















4. Conventional Method and the Comparison to Our Developed Prototype 
Zymography or substrate zymography is a technique extensively used for studying ECM 
degrading enzymes [17], MMPs, the group of enzymes responsible for implant degradation 
during wound remodeling phase. Zymography is a simple, sensitive, quantifiable and efficient 
approach for proteolytic activity analysis of cell and tissue extracts [19, 73]. It is preferred over 
other techniques such as gene expression measurement or immunoassay as most MMPs are 
encoded as inactive precursors, zymogens, and those assay are not capable of differentiating 
between the active form and inactive form. Zymogens are subject to multiple post-translational 
regulations before they become activated in the intercellular space [74, 75]. 
 
Zymography was first developed by Gross and Lapière for detecting collagen degradation in 
1962. The current widely used “substrate zymography” is the adaptation introduced by Heussen 
and Dowdle in 1980 [76]. Because MMPs are overexpressed during tumor invasion, this 
technique has gained large recognition in cancer and other research field around the world and 
has become a well-accepted conventional method for measuring MMP expression [77]. 
Zymography has been used in both research and clinical settings. It has been used to discover 
[78] and identify new types of enzymes [79] or overexpression of enzymes in multiple forms of 
cancer [80-83] and neurological diseases [84], study enzyme inhibitors [85] and identify their 
optimal dosage. Zymography is also the key technique for studying proteinases expression and 





Zymography visualizes enzymatic activity on the basis of substrate conversion. It is an 
electrophoretic method where proteins, particularly enzymes, are separated by size in a reducing 
SDS gel co-polymerized with protein substrate of choice. SDS inside the gel causes protein to 
denature into its unfolded state, rendering them to be separated without bias of their three 
dimensional shape. Upon removal of SDS, the proteins renature and exert proteolytic activity on 
the protein gel substrate [18]. The enzyme digestion could be viewed by common protein 
staining technique, Coomassie blue staining. After destaining to remove excess dyes, the 
proteolytic area will appear as white bands blue background of protein gel substrate. Within a 
certain linear range, the intensity of the band can be used to quantify the amount of protein 
associate with its activity. [17, 18] 
 
Over the past 50 years, more than 20 variants of zymography have emerged to improve specific 
aspects according to different research objectives [88].  The most relevant zymography assays 
that may be applied to our research are the substrate zymography, reverse zymography (RZ), and 
in situ zymography (ISZ). The latter 2 variants go by similar concept to substrate zymography. 
Reverse zymography is used for identification of natural inhibitors such as TIMP which also is a 
protein. Both Enzyme and substrate are copolymerized within the gel, after staining process, the 
area containing effective inhibitors is recognize as dark bands containing intact substrate against 
light background [77, 89].  
 
Although RZ shows the inhibitor potency, it does not provide any information related to cellular 




would be in situ zymography.  The sample is prepared as a thin section and is brought into 
contact with the fluorescence substrate. After incubation, the localization of particular proteolytic 
activity towards the substrate from enzyme within the biological slice sample can be viewed. 
Identification of the responsible enzymes is carried out by IHC after staining [73, 77, 90]. ISZ is 
generally used for to pinpoint enzymatic activity but the enzymatic activity can also be 
estimated. This format of zymography is the only variant that gives the net activity of the 
enzymes within the sample, not the measure of potential enzymatic activity.  
 
Firstly, quantitation of zymograms remains difficult [19]. The sensitivity of substrate 
zymography is largely governed by the staining and destaining process. Overstaining of protein 
dyes causes bands with low activity to become invisible against blue zymogram background. 
Because estimation of MMPs from sample amount is based on multipoint calibration by 
dissolving and diluting standards of different enzymes with known concentration, excessive 
destaining may bleach out bands with high activity, negating the differences between light bands, 
lowering the sensitivity of enzyme quantification. 
 
Secondly, the MMP activity demonstrated by zymography may not represent their proteolytic 
capacity in nature. Most MMPs are secreted in their inactive form, zymogens. They are tightly 
regulated and gain proteolytic activity only after specific enzymatic cleavage [91, 92]. During 
SDS-gelelectrophoresis in zymography, zymogens are unfolded and its inhibitory peptide is no 
longer attached from the catalytic site. After SDS removal, the proteins only partially refold 




of MMPs is governed by various inhibitors [93] such as tissue inhibitor of 
matrixmettalloproteinase (TIMP) which inhibits MMPs even if the enzymes are in there active 
forms. In general, MMP in solution non-covalently forms a complex with their corresponding 
TIMP. These complexes dissociate in the presence of SDS [94]. Therefore, electrophoresis step 
creates artifacts of increasing enzymatic activity and zymography may not display the actual 
proteolytic activity but rather, their possible potential in substrate digestion. 
 
Considering the practicality of MMP inhibitor screening assay, it would useful if the optimal 
dosage of each inhibitor could be determined. Because electrophoresis unavoidably increases 
enzymatic activity from that of the natural state [86, 95, 96], substrate zymography may not be 
the best option. In situ zymography offers advantage over the conventional substrate zymogrphy 
in the sense that it somewhat provide insights on the net enzymatic activity in living system. But 
both in situ and in gel zymography are time consuming and a large number of experiments needs 
to be conducted for testing out different MMP inhibitors and dosages are not  suitable for large 
scale screenings. 
 
We believe the prototype introduced in this study provides a better alternative for screening 
MMP inhibitors capable of prolonging implant lifetime to other conventional methods. As cells 
are a living units that response to external stimuli, disruption in ECM remodeling could up-
regulate MMP expression and leading to excessive ECM degradation. Results from cell-based 
assays may simulate degradation of material overtime after implant better than ISZ tissue slice 




component where no response from viable components are involved. Adopting 96-well plate 
setting, our assay can provide comparative efficacy of different inhibitors at different 
concentrations in couple to their effect on cell viability. In this way, it is possible to visualize 
optimal dosage with minimal assay runs. Because MMP and their natural inhibitors are relatively 

















5. Experimental Design and Rationale 
5.1. Overview 
Our aim is to assemble an assay prototype for screening potential inhibitors capable of slowing 
down implants degradation. Because the breakdown of implants takes place in a similar manner 
as ECM digestion, modulated by MMP catalyzed hydrolysis, our prototype is designed to test out 
the enzyme inhibitors efficacy while ensuring considerable cell apoptosis is not induced. As the 
first step towards in vivo testing, this assay is designed and resembles the physiological 
phenomena that take place around the implant while remain practical and easy to use. Cells are 
cultured in the presence of fluorescence labelled substrate that emits signals proportional to the 
extent of its degradation. The inhibitor of choice is added to the culture in a varied amount. The 
experiment is constructed to give the inhibition efficacy in terms of percentage of the 
fluorescence intensity given out by the control where MMP inhibitor is not introduced into the 
cell culture vessel. The distinctive of the signal from background, signal-to-noise ratio, from this 
assay is optimized by varying number of seeded cells, substrate concentration, reaction time and 
experiment setting, having or not having cell adhesion scaffold. Cell viability assay is conducted 
after experiments to estimate how many cells still remain alive after the assay run time. 
 
In this chapter, we describe the rationale behind the assay design; the fluorescence substrate, cell 
type selection, MMP inhibitor, and the detail of experiment planning and signal optimization in a 







In our assay, a fluorescent signal is used as our means of degradation detection. Cells are 
cultured in presence of the material representing natural implants, DQ-gelatin. DQ-gelatin is a 
commercially available gelatin heavily labelled with Fluorescein isothiocyanate (FITC) that 
emits fluorescence proportional to its own extent of degradation.  
 
In general, the occurrence of fluorescence takes place through relaxation of fluorophores from 
excited states to its original ground state emitting photons light signals [97]. In DQ-gelatin, the 
gelatin conjugated FITC are located in such close proximity that one molecule interferes with 
fluorescence of another, resulting in fluorescence quenching when DQ-gelatin is in its intact 
state. Once cleaved by gelatinolytic activity, the distance between those fluorophores increases, 
enabling fluorescence to take place after the conjugated FITC are excited, giving fluorescence 










Figure 1 Fluorescence emission in DQ-gelatin. Fluorophores in close proximity interferes with 
fluorescence activity of one another. Once cleaved, self-quenching effect is dwindled resulting in 
fluorescence emission upon excitation of the fluorophores.  
 
Enzyme 




DQ-gelatin has been used in various MMP related research where cells are cultured in its 
presence over a prolonged period [98, 99]. From those studies, many studies apply DQ-gelatin in 
solution form, many as cell substrate such as for in situ zymography to locate proteolytic activity 
or to measure the efficacy of the enzymes or in some cases, both. From these experiments we 
assume that DQ-gelatin displays low-toxicity towards living cells in culture. The dye quench 
DQ-gelatin provides a higher sensitivity than normal fluorescence conjugation and also serves as 
a good substrate since gelatin can be digested by not only gelatinases but by a large repertoire of 
enzymes (Table1). Concisely, this commercialized product is selected to portray protein based 
implants for its similarity to natural gelatin, adequate biocompatibility, as a substrate specific to 




5.3. Cell Type 
During cellular infiltration of implant in the inflammatory phase, immune cells are recruited to 
the wounded site along with fibroblast. The Macrophages and neutrophils clears out pathogen, 
their number increases depending on the implants immunogenicity while fibroblasts migrate to 
site for regenerative purpose. They are responsible for both closing up the open laceration and 
repair tissue injury to the very last stage. Their number increases until they predominate the area. 
At the wound edge fibroblasts gather and differentiate into myofibroblasts stimulating 
contraction and wound closure [100]. To restore structure and function to the damaged tissue, 
fibroblasts produce new matrix such as collagen, elastin and proteoglycan along with degrading 
provisional one. Fibroblasts are the major source of MMPs that degrades extracellular matrix 




Accordingly, all constituents of exogenous implant that are substrate specific to the secreted 
MMPs will be degraded along with ECM as a part of the regeneration process. If implants does 
not cause prolonged detrimental inflammation, the principle cell type that interacts with it is 
most probably the fibroblasts. 
 
In order to develop a prototype that resembles the physiological condition and keep the assay 
practical, fibroblast is the only one cell type used. They perform important function in wound 
healing, are widely utilized in research, are commercially available, and are relatively easy to 
purchase and maintain. The cell line utilized in this research is the standard fibroblast cell line, 
NIH-3T3, a cell line established since 1962 from Swiss albino mouse embryo tissue [104]. It is 
very robust, stable and it is relatively easy to culture in vitro. From our consideration, it is the 
suitable cell line to be incorporated into our research in order to assemble a practical assay for 
proteinase inhibitor screening. 
 
5.4. Cell Adhesion Support Scaffold 
In this experiment, we focus on the fluorescence intensity resulting from cleavage of DQ-gelatin 
by viable cell secreted MMPs. Under normal physiological conditions, the level of MMP 
expression is very low, both in vivo and in cell culture [105]. Therefore, high concentration of 
cells is required to generate adequate amount of secreted MMP in order to achieve acceptable 
fluorescence signal emission. Fibroblasts, NIH-3T3, are anchorage dependent cells that grow in 
monolayer in culture. They require appropriate substrate for cell adhesion to survive [106]. By 
introducing porous cell anchorage substrate, we may provide more surfaces for NIH-3T3 and 






Figure 2 Cryosliced fabricated polymer scaffold, scale bar = 100 µm.   
 
Our research group utilizes porous polymer scaffold as cell adhesion substrate in many projects 
[107]. The low cost and simple to fabrication scaffold is prepared by pouring aqueous free 
polyether-based thermoplastic polyurethanes (TPUs) solution into soft rubber mold filled with 
sugar. The solution seeps through space between sugar grain and fills the mold, creating porous 
structure once the sugar is dissolved out by water rinses. Data generated from analysis of the 
fabricated cryosectioned scaffold shows 67.31±8.84% pore area with very uniform density 
59.08± 4.84 µg/mm3, indicating very uniform results when compared between each scaffolds. 
 
From Figure2 high surface area could be observed, by comparing the dimension of pore size on 
the scaffold and NIH-3T3 cell, approximately 50 – 80 µm, pore size is wide enough for 3T3 to 
grow between the connected empty spaces. Therefore, the developed porous structure within the 
scaffold creates larger surface within the same experimental volume providing more area for 




experiment. Despite the attractive potential, addition of scaffold into our assay makes the assay 
preparation process more complicated. During assay development, we have also conducted 
experiments to observe whether NIH-3T3 could be maintained without scaffold. The 
experiments were prepared to have one set containing scaffold and the other not containing 
scaffold to see the comparison. MTT assay was performed to confirm cell viability after these 
experiments. 
 
5.5. MMP Inhibitor TIMP-1 and BB-94 
Degradation of protein-based implant is modulated by the same process of (granulation tissue) 
ECM remodeling, MMPs-catalyzed hydrolysis. Matrix metalloproteinases or MMPs are a family 
of structurally related zinc-dependent enzyme, collectively capable of digesting all components 
of ECM [14, 15]. The natural inhibitor of MMPs includes the tissue inhibitors of 
metalloproteinases (TIMPs), α1-proteinase inhibitor and α2-macroglobulin. TIMPs are the major 
endogenous MMP inhibitor in tissue. They maintain the balance between ECM deposition and 
degradation in physiological and biological process [16]. TIMP bind to highly conserved active 
zinc-binding sit of MMPs at molar equivalence and suppress proteolytic activity. So far, 4 
members of the TIMP family has been characterized; TIMP-1, TIMP-2, TIMP-3 and TIMP-4. 
Although different TIMPs bind to different MMPs with different affinity, both TIMP-1 and 
TIMP-2 are capable of inhibiting all known MMPs [16]. While in general TIMP plays inhibitory 






In a healthy tissue, TIMP concentration normally far exceeds MMP concentration, limiting 
proteolytic activity to only focal pericellular sites. Although the situation of TIMP and MMP 
expression in injured tissue is complicated and not fully understood [68], the activity of MMP is 
critical in wound healing. MMP is required for debridement, cut through fibrin clot and 
remodeling (granulation tissue) ECM once those migrated cells populates the wounded area. As 
an example, collagenase activity has been shown to quickly be induced and up-regulated at the 
wound edge [108], during cellular infiltration of fibrin clot [72], persist during wound healing 
and cease after the end of re-epithelialization [109]. Different MMPs is expressed and regulated 
differently during these events [102]. 
 
As MMP expressions are elevated in most human tumors [110], MMP has been held as 
promising target for cancer therapy for over 30 years [111]. So far, large number of drugs 
targeting MMP has been developed to impede metastasis and angiogenesis during tumor 
invasion [112]. Many drugs have shown compelling results in animal studies [111]; 
unfortunately, most fail later during human clinical trials [110,113,114]. One of the major 
postulated reason issues is that the synthesized MMP inhibitors are broad-spectrum chelator, 
incapable of discriminating between different zinc-dependent proteases. Because our aim is not 
to identify the best MMP inhibitor but to assemble an assay capable of discerning MMPi 
potency, therefore, the only requirement for selecting our test inhibitors would be that they do 
not cause cells apoptosis. BB-94 is one of those synthesized MMP inhibitors that has many 
successful cases in animal studies [115-118] and is the first MMPi tested in Phase I studies 
[119]. The clinical trial has continued to Phase II in Europe [120] but Phase III has been 




it is chosen as our test MMP inhibitor along with TIMP-1 that has the inhibition spectrum over 
all known MMPs. And by introducing MMP inhibitors, we hypothesize that the extent of 
proteolysis of DQ-gelatin in our assay will be reduced.  
 
The selected range to test out MMP inhibitors for our experiment is based on the estimate value 
of the MMP expression level in tissue, and the IC50 value which indicates drug’s effectiveness. 
In normal wound, the approximate collagenase expression is 0.1-1.3 µg/mL of wound fluid with 
the average of 87 µg/mL. Because TIMP-1 binds to MMP at molar equivalence and that TIMP-1 
is a costly reagent, our test range is 0.1-2 µg/mL. BB-94, or batimastat, is a potent broad 
spectrum MMP inhibitor which under physiological condition inhibits MMP with IC50 value in 
nM range; MMP-1(3 nM), MMP-2 (4 nM), MMP-3 (20 nM), MMP-8 (10 nM) [119, 123] and 
MMP-9 (10 NM) [123]. According to FDA, IC50 is the drug concentration require for 50% 
inhibition of specific biological process in vitro. Therefore, our test range for BB-94 is 20-1000 
nM. 
 
5.6. Cell Viability Testing 
To imitate implant degradation in vivo, the signal that we are interested in is the signal produced 
by viable cells. Therefore, it is imperative to verify the estimates of how many cells remain 
viable throughout the assay. The determination of viable cell number is use in many types of 
research such as drug testing, cytotoxicity test and biologically active compound screening. One 
of the most versatile assays commonly used these days is the MTT assay [124]. It involves the 
conversion of the main assay component (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 




cleaves the tetrazolium ring, transforming yellow soluble MTT into purple insoluble formazan 
crystals which dissolves in acidified isopropanol and the purple solution may then be measured 
spectrophotometrically using plate reader set to read absorbance at wavelength 570 nm. The 
higher the optical density, the higher the viable cell number counts. By preparing standards with 
known number of viable cells the information from absorption data can be interpreted.  
 
As this simple, yet accurate method is performed as the last step our MMP inhibitor screening 
assay to ensure the estimate number of viable cells are at acceptable level. Our assay is set to 
optimize MTT test measurements and avoid components that interfere with the process. MTT 
assay yields highly sensitive result at cell concentration up to 106 cells/100 µL media. The 
sensitivity may lower with the increment of cell number, high protein concentration, presence of 
phenol red and extended incubation time of MTT with viable cells [128]. Therefore, the growth 
media in our assay uses phenol red free DMEM/F-12 media instead of regular formulation, 
exclude addition of FBS and the cell viability testing is conducted outside this process is conduct 












6. Experiment Setting 
Our assay takes place in 96-well plate setting. The total reaction volume of 200 µL in our 
experiment may consist of DQ-gelatin solution dissolved in buffered fibroblast growth media, 
fibroblast and MMP inhibitor of choice. Signal optimization process is performed to achieve the 
highest signal-to-noise ratio while retaining high NIH-3T3 viability (detail discussion is reported 
in Chapter 3). We assume that, under optimized condition, the effect of inhibitor will be most 
pronounced. From previous experiments (data not shown) evaporation tremendously affected 
fluorescence measurement. Therefore, the outer most rows are not used as experimental vessels 
but are filled with sterile filtered DI water to reduce the evaporation of other inner wells of the 
96-well plate. Fluorescence emission increases as DQ-gelatin is broken down and is used as 
indicator of gelatin degradation. The more potent the inhibitor, the less fluorescence is generated.  
 
In general, a reliable assay generates a strong signal as a result of the target reaction occurrence. 
Thus, Signal optimization process is performed to achieve most distinctive fluorescence signal 
possible compared to emitted background while retaining high NIH-3T3 viability. The 
concentration of DQ-gelatin and fibroblast were varied to see the best concentration that produce 
highest signal-to-noise ratio. The experiments were conducted in 2 different settings; one having 
the cell adhesion support scaffold while the others don’t, in order to examine whether the 
scaffold is a required component in the assay.  
 
After the optimal condition to generate considerable fluorescence emission while retain high 
NIH-3T3 viability is obtained, It is used to assemble our cell based assay and test out MMP 





Now a day, a large variety of protein-based biomimetic material has been used in a wide range of 
applications [129]. Despite their great potential, after implant majority of those materials 
degrades at a faster rate than the body could regeneration. Thus, lifetime prolongation of protein 
based materials may be a practical way to improve the implants therapeutic efficacy. In general, 
degradation of protein based implants take place in a similar manner as ECM remodeling, which 
is by MMP catalyzed hydrolysis. By inhibiting proteolysis activity of these MMPs, the implant 
retention time under physiological condition may be extended. 
 
The purpose of this research is to assemble a cell-based MMP inhibitor screening assay 
prototype that resembles protein-based implant breakdown in vivo. As the dominant cell type at 
implant site, fibroblast is selected to be used as MMP source. It is cultured in presence of DQ-
gelatin, a heavily fluorescence labelled gelatin that gives off fluorescence emission proportional 
to the extent of its degradation. To investigate the effect of MMP inhibitor, the substance is 
introduced into the culture containing fibroblast and DQ-gelatin. After specific period, the 
emitted fluorescence signal is measured. The efficacy of the MMP inhibitor is obtained by 
comparing how much signal is reduced as the result of MMPi addition.  
 
Living tissue compose of viable cells, therefore in our assay, high cell viability must be 
maintained throughout the testing period. Because fibroblasts require substrates to survive and 
normally grow in monolayer in vitro, cell adhesion support scaffold is included into our assay. 
Cell viability test is conduct after every fluorescence-signal measurement to ensure fibroblasts 




Hypothesis: We believe that our assay could detect the inhibitory effect of MMPi on viable cell 
modulated protein degradation. 
 
Approach: Fibroblast, NIH-3T3, is cultured in presence of DQ-gelatin which emits fluorescence 
corresponding to how much it has been broken down. The efficacy of MMP inhibitor is 


















CHAPTER 3: NOVEL ASSAY DEVELOPMENT 
1. Rationale 
Our aim is to assemble a cell-based assay capable of evaluating MMPi efficacy on delaying rate 
of proteolysis. As our assay is designed to mimic the degradation of protein-based materials after 
implant, the signal of our interest is the fluorescence signal generated from breakdown of DQ-
gelatin by living cells thus; NIH-3T3 must remain viable after signal measurement. In this stage 
of novel assay, there are 3 main aspects of concern (1) the difference in level of generated signal 
from background fluorescence (2) cell viability and (3) practicality of the assay. An assay and 
produce high signal-to-noise ratio generated from cellular activity of viable cells that is easy to 
assemble is most desired. 
 
It has been reported that cells in unstimulated culture express low level of MMP [105], therefore, 
high number of cells may be required to generate significantly distinct signal from the 
background. But as more cells are inserted into experimental vessel, less area is available for 
cells to adhere and nutrients are consumed within shorter period, assay optimization process is 
necessary to identify highest seeded cell number that could be seeded and maintained until the 
assay is complete. DQ-gelatin concentration and experiment time is also varied to find the best 
condition that gives the most recognizable signal against background fluorescence. 
 
We have considered looking into stimulating MMP production of fibroblast in culture. Although 
MMP expressions can be induced by various exogenous signal such as cytokines and growth 
factors [105, 130], specific substance up-regulate specific MMPs, e.g. IL-1, EGF, and bFGF 




activity towards different substrate and may induce other cellular responses that are not associate 
with proteolysis. We have not found a substance to stimulate MMP production without changing 
cellular response in other aspects. Thus the act of MMP production induction itself creates the 
artifact. Therefore, our best option remains only to vary those conditions mentioned above, 
namely; the seeded cell number, fluorescence-substrate concentration and incubation time. 
 
Fibroblasts are anchorage dependent cells; by providing less than adequate surface area for cell 
adhesion, those fibroblasts may undergo apoptosis before the end of experimental process. For 
this reason, scaffold for cell anchorage is introduced into our prototype. We are aware that by 
having scaffold as a component we reduce the practicality of our assay preparation, despite the 
ease of fabrication and economical production cost. To prove the scaffold necessity, experiments 
for signal optimization were conducted in 2 settings; a) without scaffold and b) with scaffold. 
After each fluorescence measurement, MTT cell viability assay was conducted to determine the 
number of viable cells.  
 
The optimal condition we aim to identify is the condition most convenient to prepare, generate 
most dissernable signal while retaining the majority of NIH-3T3 population. Because 
optimization of one desired aspect may post negative effect on others, each factor effecting 
signal-to-noise ratio, cell viability and the practicality of the assay as important correlating 
factors that cannot be considered separately. Assay optimization process must be done to 
investigate the signal trend caused by different factors and the most appropriate condition to use 






2.1. Cell Adhesion Support Scaffold 
The porous scaffold for cell adhesion support was fabricated by pouring polyurethane solution 
into sugar filled soft silicon rubber mold. The size of each scaffold was based on the dimension 
of each well in 96-well plate. To prepare the rubber mold, 3/16” hole was punched into 1/8” 
thick soft silicone rubber sheet (McMaster-Carr) using hole-puncher. Moist sugar was prepared 
by mixing 10g of sugar with 200 µL of deionized water. The sugar was pressed into the rubber 
mold and placed in 75°C oven to dry. Polyurethane solution was prepared by mixing 1 gram of 
Tecoflex SG80-A (Thermedics) per 10 mL of dimethylacetamide, DMAc (Alfa Aesar), in round 
bottom flask. The mixture was placed on hot plate to dissolve; the temperature was set to 
approximately 60 °C with 400 rpm stirring. Once the polyurethane was dissolved, it was poured 
drop-wise onto the sugar filled rubber mold. Dry sugar was sprinkled over the mold to remove 
excess polyurethane solution then the sugar was leveled at the brim of the mold by shaving off 
sugar outside the 3/16” cavity. The mold was carefully placed into container filled with 
deionized water and was left overnight to dissolve out sugar forming porous polyurethane 
scaffold. The scaffolds were thoroughly rinsed by constantly stirring scaffold in deionized water 
for 12 hours. Rinsing was repeated 3 times to ensure removal of cytotoxic DMAc. The scaffold 
was placed in 75% ethanol for sterilization and was washed in DPBS (Gibco) 3 times before 
coating with 20 µg fibronectin (Gibco) per 1 mL sterile filtered deionized water overnight to 







2.2. Cell Culture and Propagation of NIH-3T3 
Cryopreserved NIH-3T3 (ATCC) were thawed, transferred to 15 mL centrifuge tube (VWR), 
added with 10 mL of DMEM/F12 media (Gibco) and centrifuged at 300 rpm for 5 minutes. The 
supernatant was aspirate to remove DMSO from the cryopreservation media. Cell pellets were 
suspended in fibroblast growth media (DMEM/F12 media (Gibco) supplemented with 10% fetal 
bovine serum (Gibco), 1% glutaMAX (Gibco) and 25 µg/mL gentamicin (Gibco)) and 
transferred to T-75 tissue culture flask (VWR). NIH-3T3s were maintained under standard 
condition (5% CO2, 95% humidity at 37°C). When reach confluence, NIH-3T3s were treated 
with 0.25% trypsin-EDTA (Gibco). Trypsinization was stopped by addition of growth media, 
centrifuged and resuspended. Cells were expanded using 3-6 split ratio for each passage until the 
desired number of cells was obtained. All procedure were carried out under strict aseptic 
conditions. 
 
2.3. Signal Optimization 
Signal optimization experiments took place in tissue culture treated black 96-well plate (VWR). 
The total reaction volume of 200 µL in the experiment may consist of DQ-gelatin solution 
dissolved in buffered fibroblast growth media, fibroblast and MMP inhibitor of choice. 10X 
reaction buffer was prepared using sterile filtered 0.5 M Tris-HCl, 1.5 M NaCl and 50 mM 
CaCl2. 1X reaction buffer is prepared by combining growth media, which compose of phenol red 
free DMEM/F12 (Gibco) supplemented with 1% glutaMAX (Gibco) and 25 µg/mL gentamicin 
(Gibco), with 10X reaction buffer in 9:1 ratio and was used for diluting DQ-gelatin and cell 
suspension. NIH-3T3 were treated with 0.25% trypsin-EDTA (Gibco) for cell detachment then 




supernatant were aspirate out and the cell pellets were re-suspended in reaction buffer into high 
concentration cell suspension ready for seeding. In this signal optimization process, 2 sets of 
similar experiments are conduct; setting a) using scaffold and setting b) not using scaffold. 
 
2.3.1. Setting a) 
In setting a) Cells were seeded into 96-well plates at 0.002, 0.0042, 0.014, 0.035, 0.1, 0.4, 0.8 
and 1.2 million cells per well. All wells were used except the outer most rows. DQ-gelatin was 
dissolved in reaction buffer and transfer to 96-well plate to have final concentration of 5, 10, 25 
and 50 µg/mL. The total reaction volume in each well is 200 µL. Each condition was prepared in 
triplicated. This preparation is repeated in four 96-well plates for four time-points measurement. 
After the four plates were prepared and the outer most rows is filled with sterile filtered 
deionized water, they were wrapped in tin foil to prevent light exposure. The plates were 
transferred into incubator and kept under standard tissue culture conditions for 3, 7, 10 and 15 
hours. At the designate time, the emitted signal is read using plate reader set to read florescence 
with absorption maxima approximately at 495 nm and emission maxima approximately at 515 
nm. 
 
2.3.2. Setting b) 
In setting b) the experiment were conducted in similar manner with setting a) with a few 
exceptions that cells adhesion support scaffold were used. The 2 fibronectin coated scaffolds 
were placed in each well of 96-well plate and aspirate dried. NIH-3T3 were seeded at 0.1, 0.2, 
0.4 and 0.8 million cells per well and the preparation is repeated in three plates for three time-




2.4. NIH-3T3 Viability Testing 
After every fluorescence measurement, the percent viability of NIH-3T3 for each condition was 
quantified by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay 
utilizing the conversion of yellow MTT to purple formazan by active mitochondrial 
dehydrogenase in viable cells according to the manufacturer protocol (Sigma) with minor 
modifications. Briefly, standard with known cell number was prepared and transferred separately 
to 24-well plate along with all content from each well in 96-well plate. 100 µL of 12 mM MTT 
solution, prepared by dissolving MTT in sterile DPBS (invitrogen), was inserted to each well 
follow by 700 µL of DMEM/F12 without phenol red. The plate was incubated at 37°C for 4 
hours, then 1 mL of formazan dissolving solution, 0.1 N HCI dissolved with 10% Triton-100 in 
anhydrous isopropanol, was added to each well and mix thoroughly to solubilize formazan. The 
absorbance of the purple formazan solution was measure by plate reader at wavelength 570 nm. 
Viable cell number was estimated using prepared standard curve. 
 
2.5. Mathematical Model Construction and Statistical Analysis 
Numerical data for fluorescence signal and MTT viability assay were assessed by JMP Pro11/ 
statistical analysis package. Data were compiled to visualize how DQ-gelatin concentration, 
seeded cell number and reaction run-time effect the signal-to-noise ratio and cell viability. 
Mathematical model were constructed based on those data to find the optimal condition to 





As for statistical analysis, ANOVA was performed to determine statistical significance between 
groups, i.e. inhibitor or concentration, followed by Tukey test once significant difference was 
























3. Result and Discussion  
To find the specific condition that would produce highest signal-to-noise ratio while maintaining 
high cell viability, assay optimization process was conducted. The experiments were prepared in 
two settings; setting a) without scaffold and setting b) with scaffold. Seeded cell number, DQ-
gelatin concentration and incubation time were varied. At designate time, florescence was 
measured and MTT assay was performed to estimate cell viability. The emitted fluorescence is 
converted into signal-to-noise ratio to signify how different the cell-related emitted signals are 
from the background fluorescence. Absorbance from MTT assay was converted to cell number 
estimates based on the known prepared standards. The signal-to-noise ratio and NIH-3T3 
viability were combined and assessed using JMP pro11 formed into mathematical model to 
obtain optimal condition that generate high signal-to-noise ratio while keeping the cells alive. 
From the generated model and statistical analysis, the factors and their significance on signal-to-
noise ratio and cell viability could be illustrated. 
 
3.1. Setting a) 
 
 
Figure 3 Analysis of variance. ANOVA of setting a) signal-to-noise ratio in signal optimization 





Analysis of variance suggests that there are significant differences resulting from varying 
experiment preparation conditions; seeded cell number, DQ-gelatin concentration and incubation 
time. From the complied signal-to-noise ratio, mathematical model or prediction plot with R2 
value of 0.92 were constructed. In statistical analysis, R2 provides measure of how well the 
model represents the data in terms of proportion of total variation of outcomes explained by the 
model, ranging from 0-1 [133]. With R2 of regression plot equivalent to 0.92, the ability of the 
constructed model to predict real value is relatively very accurate.  
 
 
Figure 4a Actual by predicted plot. All actual collected signal/noise data are displayed as black 





Figure 4b Actual by predicted plot. Signal-to-noise ratio from experiments with seed cell 
number between 0.002-0.1 million cells. 
 
 







Figure 4d Actual by predicted plot. Signal-to-noise ratio from experiments with seed cell 
number between 0.8-1.2 million cells.   
 
Figure 4 shows actual signal-to-noise ratio from collected data as round dots plotted against the 
established mathematical model displayed in red line. The signal-to-noise ratio of experiments 
with seeded cell number equals to 0.002-0.1 million cells, 0.4 million cells and 0.8-1.2 million 
cells are presented as black dot on figure 4b), 4c) and 4d) respectively. From the figure, it could 
be concluded that as the number of seeded cell increases, the higher signal-to-noise ratio 
produced.  
 
The predicted plot or the mathematical model generated from collected signal-to-noise ratio via 
JMP consist of 3 experimental variables; seeded cell number, experiment time and DQ-gelatin 
concentration. Statistical analysis of the mathematical model (Figure 5) shows the extent of 




shown in orange are highly significant while the values shown in red are significant at 0.05 level. 
By far, the number of seeded cell place highest impact on signal-to-noise ratio production. The 
terms shown below are used to construct our mathematical model displayed on figure 5. Once 
included in the model, terms with higher significance will cause predicted value to be closer to 
the collected data, resulting in constructed model with higher R-square value. 
 
To investigate how each experimental variable; seeded cell number, DQ-gelatin concentration 
and incubation time, affects the trend of signal-to-noise ratio, the generated data were plotted 
against varying value of 2 selected factors in 3 dimensions. In Figure 6a) on horizontal axis are 
the seeded cell number and the DQ-gelatin concentration. The signal-to-noise ratio data are 
shown as black dots against the green sheet model. The vertical lines of dots are data generated 
at the same seeded cell number and DQ-concentration with different incubation time. The higher 
signal-to-noise ratio is the shorter the incubation time (data not shown). Similarly, in Figure 6b) 
the seeded cell number and incubation time are displayed on horizontal axis. The vertical lines of 
dots are signal-to-noise ratio produced by experiments with same seeded cell number and 
incubation time but at different DQ-concentration.  
 
The prediction profiler enables a clear visualization of how each experimental variable affects 
the trend of signal-to-noise ratio at specific condition. On Figure 6 c), the trend at conditions that 
produce the highest signal-to-noise ratio is shown. The shortest incubation time, highest DQ-
gelatin concentration and largest number of seeded cell provides the best/most preferable 




variable affects the signal-to-noise ratio. The effect of variation in seeded cell number on signal-
to-noise ratio is by far greater than that of concentration and incubation time.  
 
 
Figure 5a Sorted parameter estimates and mathematical equation of constructed model.  9 
terms of parameter estimates that are used to generate signal/noise ratio model 
 
 
Figure 5b Sorted parameter estimates and mathematical equation of constructed model. 









       1.162240 + (1.347825 * Seeded Cell # )  + [(-0.850079) * (Seeded Cell # - 0. 281786)2] +  
       [(-0.0194441) * (Hours - 8.735499) * (Seeded Cell # - 0.281786)] + [(0.003620) *  
       (Conc - 22.436195) * (Seeded Cell # - 0. 281786)] + ((-0.001693) * Conc) +  
       [(0.000080) * (Conc - 22. 436195)2] + (0.002814 * hours) + [(-0.000122) *  
       (Hours – 8.735499) * (Conc - 22.436194)] + [(-0.000302) * (Hours - 8.735499)2]  
    Intercept + [(1.347825)  *  1 ] + [(-0.850079) * 2 ] + [(-0.194441) * 3  ] + [(0.003620)  *  4 ]  
             + [(-0. 001693)*  5 ] + [ (0.000080) * 6 ] + [(0. 002814) * 7  ] + [(-0.000122) *  8 ] 
        + [(-0.000302) *  9 ]  
 
Figure 5c Sorted parameter estimates and mathematical equation of constructed model. 
Mathematical model for signal-to-noise ratio prediction. Term Seeded Cell # refers to seeded cell 
number, Hours refer to incubation time and Conc refers to DQ-gelatin concentration 
 
 
Figure 6a 3-Dimensional plot of signal-to-noise ratio. Signal-to-noise ratio data is plotted 
















Figure 6b 3-Dimensional plot of signal-to-noise ratio. Signal-to-noise ratio data is plotted 
against seeded cell number and incubation time. 
 
 
Figure 6c 3-Dimensional plot of signal-to-noise ratio. Prediction profiler set at the optimal 
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After the signal to noise ratio trend has been established, we identify the significant difference 
within each variable by performing Tukey test, shown in Figure 7 (n=3, p<0.05). Signal-to-noise 
ratio barely increase as incubation time is prolonged and does not linearly vary in according to 
DQ-gelatin concentration but significantly escalates as seeded cell number is increased. Despite 
the modest value of signal-to-noise ratio, all conditions of seeded cell number produce 
significantly distinct signal-to-noise ratio from the no cell control. This result confirms the 
reliability of our assay. 
 
In conclusion, the signal-to-noise ratio generated from DQ-gelatin break down is largely 
governed by seeded cell number. Their significant influence is supported by the 2-dimensional 
plot in Figure 3, parameter estimates in Figure 4, the slope of signal-to-noise ratio trend in figure 
6 and from statistical analysis. Signal-to-noise ratio is also affected by DQ-gelatin concentration 
and incubation time but in a lesser extent. The result from constructed model may differ a little 
from statistical analysis in figure 7. This is because the model shows the prediction at specific 
condition, (n=3), e.g., at certain DQ-gelatin concentration, seeded cell number and incubation 
time but in Tukey-test, one condition of one vaiable is fixed consequently, the information is the 
average of the estimate over a wide range of condtions and the signal-to-noise trend varies as the 
governing experimental condition changes. Therefore, if one is interested to predict signal-to-
noise ratio or trend at specific condition, it would be more accurate to rely on the constructed 
model, figure 6, rather than the overall result separate by certain category presented by Turkey 






Figure 7 Turkey Test analysis on each experimental viariable.  Tukey test on incubation time 
(n=108), seeded cell number and (n=54), DQ-gelatin concentration (n=108).  
 
Cell Viability Test 
After fluorescent signal measurement, MTT cell viabiliy test is performed to estimate the number 
of remaining viable cells. Yellow MTT solution is converted to purple formazan crystal via 
components of viable cells and is measured by absorption. The approximate number of viable 
cell can be obtained from comparing obtained result against a standard curve. The number of 
viable cells are translate and presented as percentage of the initial seeded number. 
 
Our aim is to verify usable conditions that generates high signal-to-noise ratio while maintaining 
high viable cell percentage. It is not our focus to study how experimental variable excerts impact 
on cell viability and proliferation. The produced cell viability percentage used for statistical 
analysis and to construct a mathematical model having each experimental variable set as non-
corelating factors. The analysis of varience suggest there are significance difference between cell 
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viability percentage resulting from different conditions (n=3, p<0.05). The obtained model has 
the R2 value of 0.93 showing relatively high accuracy in predicting actual percent viability. 
 
 
Figure 8a Statistical analysis of cell viability test setting a). Actual data plotted against 
predicted model as black dos against red line 
 
 







Figure 8c Statistical analysis of cell viability test setting a). Parameter estimates, displaying 
the significance of parameters on model fitting 
 
Figure 9 gives a rough estimation that cell viability percentage is majorly dictated by the seeded 
cell number. The lower the number of cell initially seeded the higher percent viability. The over 
100% value in cell viabliliy gives an indication of cell ploriferation. As the number of seeded  
cell is increased, the viability percentage drops. The assumtion the the cell viability percentage is 
largely affected by seeded cell number is also confirmed by the relatively high F-ratio in 
parameter estimates, Figure 8c). 
To conclude signal optimization setting a), signal optimization experiment sets without scaffold, 
the experiment conditions that generates the our highest range of signal-to-noise ratio could not 
maintain a satisfactory level of cell viability while those that are capable of maintaining more 
than 80% viability produces less discernible signal. Therefore, although all level of seeded cell 
number produce statistically significant distict signal from the background, the conditions that 




alternative that could produce acceptable signal strength while keeping more cells alive 
throughout the course of experimental procedures. 
 
 
Figure 9a NIH-3T3 Cell viability percentage. Cell viability is reported in percent of the 
original seeded number. Viability percentage is plotted against seeded cell number and 



















Figure 9b NIH-3T3 Cell viability percentage. Cell viability is reported in percent of the 









Figure 10 Turkey Test analysis on percent cell viability of different seeded cell number. 
Least square mean value represents cell viability percentage at the seeded cell number in milion 













3.2. Setting b) 
 
 
Figure 11 Analysis of variance. ANOVA of setting b) signal-to-noise ratio in signal 
optimization process; treating each specific condition; concentration and cell seeding number as 
one treatment (n=3, p<0.05) 
 
In these set of experiments, cell adhesion support scaffold is included into the assay to verify 
their positive impact on cell viability and weather they cause changes in experimental results. 
Analysis of varience suggest statistical significance between each group of experiments prepared 
by varying seeded cell number, DQ-gelatin concentration and incubation time, Figure 11 (n=3, 
p<0.05). Out of 144 conditions, 6 outliers were excluded. The constructed mathematical model 
from compilation of signal-to-noise ratio data and statistical analysis has R2 of 0.82, figure 12a), 
which is relatively high, thus it is possible for the model to closely predict the real values 
experimental values. The mathematical model consist of terms listed in figure 12b), having 









Figure 12a Mathematical model. Actual signal-to-noise data are displayed as black dots against 
red predicted plot.  
 
 









   0.962831 + (0.119493 * Days) + (1.437393 * Seeded Cell#) + (0.004032 * conc) +  
   [(-0.38034) * (Day-3)2] + [(0.209935) * (Day-3) * (Seeded Cell# - 0.370803)] +  
   [(-1.945501) * (Seeded Cell# - 0.370803)2] + [(0.000543) * (Day-3) * (conc – 22.518248)] +     
   [(0.000641) * (Seeded Cell# - 0.370803) * (conc – 22.518248)] +  
   [(-0.000107) * (conc – 22.518248)2] 
 
Figure 12c Mathematical model. Equation for the constructed mathematical model; Term 




Figure 13a 3-Dimensional plot of signal-to-noise ratio. Signal-to-noise ratio data is plotted 














Figure 13b 3-Dimensional plot of signal-to-noise ratio. Signal-to-noise ratio data is plotted 
against seeded cell number and incubation time. 
 
 
Figure 13c 3-Dimensional plot of signal-to-noise ratio. Prediction profiler set at the condition 










Reaction Time  
(Day) (5) 







To study how seeded cell number, DQ-gelatin concentration and incubation time affect the 
signal-to-noise ratio trend, the collected data are plotted against these factors and are displayed 
as two 3-dimensional plots on figure 13. It is noticeable that the signal-to-noise ratio trend shifts 
a little as one factor is varied. For example, the effect of seeded cell number increases as the 
number of days and DQ-gelatin is increased. This could be visualized as the increase in steepness 
of the slope when comparing the trend line between day 1 and day 5, and of DQ-gelatin 
concentration at 5 and 50 µg/mL.  
 
The slope increase may be caused by the more ease of access for cells when more DQ-gelatin 
were available, therefore, there were more opportunities for DQ-gelatin degradation to take 
place. Also, by prolonging the incubation period, there is longer time for cells to for cell 
modulated proteolysis, as a result, the effect of seeded cell number are more pronounced. 
 
On the prediction profiler, the trend at the condition that generates the highest signal-to-noise 
ratio is displayed. From figure 13, the optimal condition would be the highest seeded cell, 
highest DQ-gelatin concentration and the longest incubation time. The statistical significance of 
each varied variables is verified by Tukey Test, figure 14. Changes in DQ-gelatin concentration 
does not cause large distinction in resulting signal-to-noise ratio while changes in all levels of 
seeded cell number and incubation time cause the resulting signal-to-noise ratio to be statistically 












Figure 14 Turkey Test analysis result. Turkey test were performed on percent cell viability of 
different incubation time, seeded cell number and DQ-gelatin concentration. Least square mean 
value represents cell viability percentage at the condition level in million cells. Levels not 
connected by the same letters are statistically different. 
 
Cell Viability Test 
Following fluorescence measurement of signal optimization setting b), cell viability check was 
conducted. Analysis of variance shows no statistical significant difference resulting from varying 
seeded cell number, DQ-gelatin concentration and incubation time, (n=3, p=0.05), Figure 15. 
Therefore, mathematical model of viable cell percentage will not been constructed for this 
setting. From analysis of raw data, the viability percentage of the condition contributing to 
highest signal-to-noise ratio is 251.48 ± 42.44% indicating that there is more than adequate 
number of viable cells persisting throughout the experiment. Therefore, the concluded best 
condition in signal optimization experiments setting b) is the condition with seeded cell number 
of 0.8 million cells, 5 days incubation period and 50 µg/mL of DQ-gelatin concentration. 
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Figure 15 Analysis of variance for cell viability of setting b) Anova on NIH-3T3 viability in 
signal optimization setting b); treating each specific condition; concentration and cell seeding 
number as one treatment (n=3, p<0.05). The analysis were not able to detect significant 
difference between each conditions 
 
3.3. Overall Results and Discussion 
From our experiments, as the incubation time is extended, the level of background fluorescence 
increases, therefore, our measured fluorescence data is converted to signal-to-noise ratio to 
maintain the consistency and to report the distinctiveness of the emitted fluorescence.  
 
In setting a) experiment without cell adhesion support scaffold, mathematical model for signal-
to-noise ratio indicates that the main contributing factor to signal-to-noise level is the seeded cell 
number. But because the condition that contributes to higher signal range cannot maintain 
satisfactory amount of cell viability, the governing mathematical model is the percent viability 
model, not the model for signal-to-noise ratio. From percent viability model, the predicted 
optimal conditions were the experiments with seeded cell number of 0.35 million cells incubated 
with 25 µg/mL of DQ-gelatin for 15 hours with signal-to-noise ratio of 1.23 ± 4x10-2. This 
deviates a little from the actual highest signal-to-noise ratio is 1.40 ± 0.05 from experiment with 




The optimal condition to pick from these options is somewhat questionable. All in all, because 
the conditions with higher signal-to-noise ratio cannot support NIH-3T3 to remain viable, we 
suggest seeking other alternatives for cell-based assay assembly instead of considering for best 
options out of experiments from setting a).  
 
In setting b) experiment with cell adhesion support scaffold, analysis of variance cannot detect 
the significance between different treatment conditions thus reliable mathematical model cannot 
be constructed. From rough cell viability data analysis, majority of the experiments provide 
considerable capacity to maintain cell viability, e.g., over 80% viability. The mathematical 
model for signal-to-noise ratio suggest the most suitable condition for signal optimization 0.8 
million cells, 5 days incubation period and 50 µg/mL of DQ-gelatin concentration. This 
suggestion agrees with the actual conducted experimental condition that generates the highest 
signal-to-noise ratio of 2.67 ± 0.23. MTT test confirms the capacity of the cell adhesion scaffold 
to prevent cell apoptosis by showing viability percentage of 251.48 ± 42.44%. By comparing 
highest obtained signal-to-noise ratio and cell viability of setting a) and setting b), cell adhesion 
scaffold play role in increasing signal-to-noise ratio and maintain cell viability therefore is worth 
incorporating to be a part of the assay despite the reduction in practicality from assay 
preparation. 
 
From all experimental condition conducted, the highest attainable signal-to-noise ratio was 2.67 
± 0.23. This small number coincides with what has been mentioned in Ravanti et al. that cells in 




only small extent of florescence signal could be generated, resulting in low value of signal-to-
noise ratio. Despite these concerns, the signal-to-noise ratios produced by different conditions 
are all statistically different from background fluorescence. These results suggest that even 
though those NIH-3T3S produce small amount of MMPs, it is adequate to generate statistically 
distinct signal and therefore, it could be concluded that cell based assay is a feasible method for 

















4. Conclusion  
The objective of assay optimization process is to identify the condition that is most practical to 
prepare that provides the highest signal-to-noise ratio while retaining an acceptable number of 
viable NIH-3T3 cell. The optimization process is conduct by culturing NIH-3T3 cells in presence 
of DQ-gelatin which emits fluorescence signal proportional to its extent of degradation. The 
number of seeded cell, DQ-gelatin concentration and the incubation time is varied. The 
experiments in conducted in 2 sets; setting a) without cell adhesion support scaffold and b) with 
the scaffold. This is done to verify the necessity of the scaffold.  
 
The highest signal-to-noise ratio of the condition in setting a) that could maintain more than 80% 
of originally seeded NIH-3T3 was 1.23 ± 4x10-2 while in setting b) the highest signal-to-noise 
ratio is 2.67 ± 0.22. Therefore, we conclude that the cell adhesion support scaffold is a necessary 
component of our assay the increases the capacity to retain cell viability and enhance the signal 
intensity.  
 
Because of the distinctive signal generated from cell driven DQ-gelatin breakdown and the high 
percentage of maintained NIH-3T3, we anticipate that a cell-based assay that resembles protein-
based implant break down in vivo could be assembled. Upon introduction of MMPis the 
breakdown of DQ-gelatin could be and the reduction in fluorescene emission could be measured. 
The extent of fluorescence emission indicates the proteolytic inhibitory efficacy of the inhibitor. 
Based on these assumptions, MMP inhibitor screening assay could be constructed and apply to 




The identified condition that provides the highest signal-to-noise ratio that can maintain NIH-
3T3 viability is the experiment in setting b) with seeded cell number of 0.8 million cells, 5 days 
incubation period and 50 µg/mL of DQ-gelatin concentration. This condition will be used in 





















CHAPTER 4: CELL-BASED MMP INHIBITOR SCREENING ASSAY 
1. Rationale 
After the optimal experiment condition has been determined, it is used to assemble our cell-
based MMP inhibitor screening assay. NIH-3T3 is cultured on cell adhesion support scaffold at 
0.8 million cells/well, in presence of 50 µg/mL DQ-gelatin with varying amount of MMP 
inhibitor, determined in prototype optimization. After 5 days the emitted fluorescence is 
measured at designate time point. This signal from culture without MMP inhibitor is used as a 
control to compare with emitted signal from cultures with MMP inhibitor. When the inhibitor 
binds to zinc binding domain of MMP, the enzyme proteolytic activity is deactivated leading to 
reduction in fluorescence emission because of less degradation of DQ-gelatin has taken place. 
From this logic, we believe the inhibitory effect of MMPi could be determined and used this 
quantification as means for screening potential MMPi for protein based implant lifetime 
prolongation. 
 
The efficacy of the inhibitor is reported in percent reduction of fluorescence signal from culture 
without MMP inhibitor. The more effective the inhibitor, the lower signal is generated. Selected 
MMP inhibitors are added in a varied concentration to determine the optimal dosage. Cell 
viability assay is performed to ensure high percentage of seeded NIH-3T3 remain alive 
throughout the assay. Statistical analysis was performed to see the result precision, the 







2.1. Assay Preparation 
Material required, reagent preparation, fibroblast culture, scaffold fabrication, and viability assay 
were carried out as mentioned in the methodology section of chapter 3. MMP inhibitor screening 
assay experiments take place in tissue culture treated black 96-well plate (VWR). Growth media 
as used in signal optimization was mixed with 10X reaction buffer in 1:9 ratio to be used as 
reaction buffer for diluting DQ-gelatin and cell suspension. NIH-3T3 were detached, spun-down 
and made into high concentration cell suspension ready for seeding.  
 
2.2. MMP Inhibitor Screening Assay 
The MMP inhibitor screening assay took place in tissue culture treated black 96-well plate 
(VWR). The fibronectin coated scaffolds were aspirate dried and inserted into each wells of three 
96-well plates except the outer most rows. Cells were seeded into scaffold 0.8 million cells per 
well. DQ-gelatin was dissolved in reaction buffer and transfer to 96-well plate to have final 
concentration of 50 µg/mL. The concentration of BB-94 and TIMP-1 were varied from 20-1000 
nM (9.55-477.64 ng/mL) and 0.1-2 µg/mL respectively. The total reaction volume in each well is 
200 µL. Each condition was prepared in triplicated. The outer most rows were filled with sterile 
filtered deionized water and the plates were wrapped in tin foil to prevent the plates from light 
exposure. The 96-well plates were transferred into incubator and kept under standard tissue 
culture conditions 5 days. At the designate time, the emitted signal is read using plate reader set 
to read florescence with absorption maxima approximately at 495 nm and emission maxima 




2.3. NIH-3T3 Viability Testing 
After each time point measurement, the percent viability of NIH-3T3 for each condition was 
quantified by MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) assay 
following the same method as in section 2.4. NIH-3T3 viability testing from previous chapter. 
The estimate of viable cell number is proportional to the absorbance value at 570 nm. 
 
2.4. Statistical Analysis 
Numerical data for fluorescence signal and MTT viability assay were assessed by JMP Pro11/ 
statistical analysis package. Analysis of variance (ANOVA) were performed to determine 
statistical significant between groups, i.e. inhibitor or concentration, followed by Tukey test once 


















3. Result and Discussion 
3.1. MMP Screening Assay 
Following incubation of 50 µg/mL DQ-gelatin with NIH-3T3 in presence of either TIMP-1 or 
BB-94 at different concentrations under standard tissue culture condition (5% CO2, 95% 
humidity at 37°C) for 5 days, the emitted fluorescence was measured. TIMP-1 was tested at 0.1, 
0.375, 0.75 and 2 µg/mL and BB-94 at 20, 250, 750 and 1000 nM. The ranges of MMP inhibitor 
concentration were selected based on their potency under physiological conditions to elicit the 
ability of our prototype in MMP inhibition detection not for efficacy comparison. Statistical 
analysis suggests that the signal generated in consequence of culturing cells in presence of DQ-
gelatin is significantly different from the background fluorescence (n=3, p<0.05), detail 
discussion mentioned in prototype development.  
 
From the 96-well plate used as experiment vessel, fluorescence emission from well containing 
MMP inhibitor was compared to wells without inhibitors to visualize the enzyme inhibition 
potency as the level of fluorescence correlated with the extent of DQ-gelatin break down. The 
concentration of each inhibitor was varied, each condition were prepared in triplicates. The data 
obtained is present as bar chart in the form of percentage of the DQ-gelatin degradation without 
the inhibitory effect of MMP inhibitor (Figure 16). TIMP-1 demonstrated maximum inhibition 
potency of 60.00±27.41 % at the concentration of 2 µg/mL and BB-94 displayed maximum 





The initial assessment using Analysis of variance (ANOVA) considering each distinct condition, 
type of inhibitor and concentration of inhibitor as one treatment shows significant difference 
between different treatment (p<0.05), (Figure 17a). To determine which pairS of treatments are 
statistically different another ANOVA and Tukey test were performed. The analysis suggests 
that there is significant difference between the inhibitory effect of TIMP-1 and BB-94 (Figure 
17b) but variation in their concentration does not influence the inhibitor efficacy in a significant 
level (Figure 17c). To conclude the overall efficacy of both MMP inhibitors over the chosen 
concentration range, TIMP-1 post 43.80±18.62% inhibitory effect while BB-94 shows 
63.67±7.5% degradation inhibition over the experimental period of 5 days. 
 
To compare inhibition efficacy of BB-94 and TIMP-1, BB-94 possesses higher inhibition 
potency with smaller standard deviation. Because there are no detectable statistical difference in 
the inhibitory effect of BB-94 the best concentration would be the lowest concentration, 20 nM. 
Despite TIMP-1 does not have detectable significant difference between each concentration, T3 
has no significant inhibitory effect, thus, it is best to select the concentration report to be most 
potent, 2 µg/mL. As there is no statistical difference in the efficacy of these 2 conditions, it could 
be roughly concluded that BB-94 is approximately 200 times more potent than TIMP-1 at 









Figure 16a Degradation of DQ-gelatin and MMP inhibitor efficacy measurement.  
Degradation of DQ-gelatin in presence of MMP inhibitor. Timp-1 and BB-94 were tested at 
concentration 0.1, 0.375, 0.75 and 2 µg/mL and 20, 250, 750 and 1000 nM respectively. 
 
 
Figure 16b Degradation of DQ-gelatin and MMP inhibitor efficacy measurement.  
Inhibition efficacy of MMP inhibitor, the reduction from 100 percent degradation indicates the 


































































Figure 17a Statistical analysis. ANOVA of MMP inhibitor screening assay result; treating each 
concentration of each inhibitor as one treatment (n=3, p<0.05) 
 
 
Figure 17b Statistical analysis. b) ANOVA of MMP inhibitor screening assay result; treating 
each type of inhibitor as one treatment (n=12, p<0.05)  
 
 
Figure 17 Statistical analysis. Tukey test on cell viability of different conditions, levels not 




3.2.NIH-3T3 Viability Testing 
 
 
Figure 18 Analysis of variance on cell viability after MMP inhibitor screening assay. 
ANOVA of NIH-3T3 viability; treating each specific condition; each type of inhibitor and the 
concentration as treatment (n=3, p<0.05) 
 
After MMP inhibitor screening assay was complete, fluorescence measurement taken, MTT 
viability assay was performed to ensure cells remain alive throughout 5-day incubation period. 
MTT solution was insert into each experimental compartment, mitochondrial dehydrogenase in 
viable cells would convert yellow MTT into purple formazan crystal which could be detected by 
measuring absorbance at 570 nm after solubilization. Analysis of variance shows no significant 
difference between each conditions (n=3, p=0.05), Figure 18 over 5 days, NIH-3T3 in each 
condition had proliferated to 238±35.17% the original seeded cell number. These results suggest 









The purpose of Cell-based MMP inhibitor screening assay experiments is to observe whether our 
developed assay could display the inhibitory potential of our selected MMP inhibitors as we have 
postulated. We hypothesized that the introduction of MMP inhibitor would reduce the proteolytic 
activity within the experimental volume, which could be determined by the reduction of emitted 
fluorescence caused by DQ-gelatin breakdown. Experiment were carried out using the optimized 
conditions obtained from novel assay development process, 0.8 million cells seeded on scaffold 
incubated for 5 days in presence of 50 µg/mL of DQ-gelatin, together with varied concentrations 
of MMP inhibitors; 0.1-2 µg/mL and 20-1000 nM for Timp-1 and BB-94. The outcomes were of 
satisfactory that each experiment containing MMP inhibitor shows reduction in fluorescence 
signal when compare to the control group that has no MMP inhibitor within the experiment. 
TIMP-1 exhibit maximum inhibition potency of 60.00±27.41 % at the concentration of 2 µg/mL 
and BB-94 72.59±4.75 % at the concentration of 1000 nM after 5 days incubation. From these 
results, we conclude that our constructed novel cell-based assay could be used to determine the 









CHAPTER 5: CONCLUSION AND RECOMMENDATION FOR FUTURE RESEARCH 
We believe that based on fluorescence emission emitted from DQ-gelatin we could estimate the 
inhibitory efficacy of MMPi in protein proteolysis and use this concept to construct MMP 
inhibitor screening assay. From assay prototype development, it has been demonstrated that cell 
driven breakdown of DQ-gelatin created a reliable fluorescent signal that is statistically different 
from the background noise. The most favorable condition for signal optimization that can 
maintain NIH-3T3 viability defined during the development is used as the setting for MMP 
inhibitor screening assay. 
 
The efficacy BB-94 and TIMP-1, our MMP inhibitor of choice were examined. The 
concentration range of these inhibitor were based on the estimate value of MMP in tissue and 
their half maximal inhibitory concentration value; Timp-1 0.1-2 µg/mL and BB-94 20-1000 nM 
or 9.55-477.64 ng/mL. After 5 days incubation of 0.8 million NIH-3T3 cells in presence of 50 
µg/mL DQ-gelatin with varying amount of MMP inhibitor, the fluorescence signal is measured. 
The signal was translated into the percentage of the fluorescence signal emitted by the control 
where no inhibitor was added and the decrease in the value is reported as the inhibitor efficacy of 
the inhibitor. 
 
From our assay, TIMP-1 exhibit maximum inhibition potency of 60.00±27.41 % at the 
concentration of 2 µg/mL and BB-94 72.59±4.75 % at the concentration of 1000 nM. The 
statistical analysis showed no significant difference between each concentration of inhibitors. 




chosen concentration range for TIMP-1 is 43.80±18.62% and BB-94 is 63.67±7.5% over the 
experimental period of 5 days. BB-94 proves to be the more attractive potential MMP inhibitor 
for implant lifetime prolongation with its higher inhibitory efficacy, less in result variations and 
relatively lower cost.  
 
By being capable of displaying optimal concentration and efficacy of MMPi while maintaining 
cell viability we believe our novel cell-based assay is a feasible assay for inhibitor screening that 
represents the complex degradation process of protein based implant in biological system better 
than the current conventional enzyme-based methods. Because of the high cost of MMPs, our 
assay may serve as a less costly alternative and would shorten the process of cytotoxicity test if 
the chosen MMP inhibitor would later be tested in the in vivo experiment. 
 
For future directions, the improvements of the novel assay could be conducted by simplifying 
cell adhesion support scaffold fabrication process by changing types of materials and optimizing 
their capacity to support viability of high cell number. In this way, the assay would gain more 
practicality and would be more easy to use. 
 
Other than the capability of the assay, from this research, we may be able to conclude that MMP 
inhibitors may be used to impede protein degradation process, thus, is a potential substance that 
could be used to be co-delivered with protein based material to extend the implant retention time 
in vivo. Further researches are required to before this scheme may successfully take place. As 




uninterrupted, introducing MMP without retaining them to the implant cite may bring about 
negative side effects. Furthermore because MMP modulated proteolytic degradation is confined 
to a close space near cell periphery [56], MMPi efficacy would detrimentally decrease if let 
dispersed to surrounding area. For this reason, introduction of MMP inhibitor may be a feasible 
means of extending lifetime of protein based implants but there is still considerable distance 
before their actual usage. A proper conjugation method to couple MMP inhibitor to the implants 
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